Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/14/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. SNDK
6. HTFL
7. ADYEN:NA
8. ADYYF
9. WDAY
10. DVLT

Go back to Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)
(NASDAQ: ACRS) Delayed: 5.78 -0.08 (1.37%)
Previous Close $5.86    52 Week High $33.88 
Open $5.82    52 Week Low $14.12 
Day High $5.86    P/E N/A 
Day Low $5.64    EPS $0.00 
Volume 666,223